Cardinal Health (CAH)
(Delayed Data from NYSE)
$112.55 USD
+0.57 (0.51%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $112.56 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$112.55 USD
+0.57 (0.51%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $112.56 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth B Momentum A VGM
Zacks News
Here's Why You Should Buy Align Technology (ALGN) Stock Now
by Zacks Equity Research
Investors remain optimistic about Align Technology (ALGN), backed by Invisalign's strong potential and impressive collaborations.
Here's Why Cardinal Health (CAH) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Tandem Diabetes (TNDM) Gains From Innovation Amid Competition
by Zacks Equity Research
Tandem Diabetes (TNDM), in 2024, intends to advance its AID algorithm and expand its indications to include people living with Type 2 diabetes.
Stryker (SYK) Acquires SERF SAS to Aid Its Orthopedic Segment
by Zacks Equity Research
Stryker (SYK) completes its acquisition of SERF SAS, a France-based joint replacement company. With this acquisition, Stryker aims to boost its orthopedic division in the European region.
Bruker Corporation (BRKR) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Bruker Corporation (BRKR) outperforms the industry due to its strengthening portfolio and robust quarterly results.
Thermo Fisher (TMO) Inks Deal to Develop Companion Diagnostics
by Zacks Equity Research
Thermo Fisher's (TMO) new partnership with Bayer AG is likely to help increase the latter's precision cancer therapies.
Should Value Investors Buy Cardinal Health (CAH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Reasons to Hold Patterson Companies (PDCO) in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.
Here's Why You Should Hold McKesson (MCK) in Your Portfolio
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Phibro Stock (PAHC) Rises 7% YTD: Will the Run Continue?
by Zacks Equity Research
Investors are optimistic about Phibro (PAHC), led by the introduction of new products and upbeat guidance.
3 Reasons Growth Investors Will Love Cardinal (CAH)
by Zacks Equity Research
Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.
Here's Why You Should Retain Nevro (NVRO) Stock for Now
by Zacks Equity Research
Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.
GE HealthCare (GEHC) Renews HealthCare Alliance With Hartford
by Zacks Equity Research
GE HealthCare (GEHC) and Hartford Healthcare announce the renewal of The Care Alliance. The renewal will extend the collaboration through 2030, which started back in 2016.
UnitedHealth (UNH) Faces Investigation Following Cyberattack
by Zacks Equity Research
A cyberattack on UnitedHealth's (UNH) subsidiary, Change Healthcare, last month continues to impact its healthcare services. The HHS investigation will determine any breach of protected health data.
Reasons to Add Stryker (SYK) Stock in Your Portfolio Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.
Revvity's (RVTY) New Launch to Boost Research Productivity
by Zacks Equity Research
Revvity's (RVTY) latest next-generation suite is likely to enhance research productivity and innovation.
Here's Why You Should Retain National Vision (EYE) Stock Now
by Zacks Equity Research
The strong execution of strategic initiatives and robust financial stability bode well for National Vision (EYE).
Walgreens' (WBA) AllianceRx Pharmacy Will Distribute VIVJOA
by Zacks Equity Research
Walgreens' (WBA) specialty pharmacy patients now have exclusive access to 240+ limited distribution drugs.
HealthEquity (HQY) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in the majority of its segments, in the fourth quarter of fiscal 2024.
Here's Why You Should Hold Surmodics (SRDX) Stock for Now
by Zacks Equity Research
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
Merit Medical (MMSI) Launches FDA-Cleared Micro-Access System
by Zacks Equity Research
Merit Medical (MMSI) announces the launch of its latest FDA-approved Micro ACE Advanced Micro-Access System, which is likely to benefit interventional treatments using micro access.
Here's Why You Should Retain Accuray (ARAY) Stock for Now
by Zacks Equity Research
Accuray's (ARAY) solid product demand raises optimism about the stock.
Here's Why Cardinal Health (CAH) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Investors Should Buy Phibro (PAHC) Stock Now
by Zacks Equity Research
Phibro's (PAHC) diversified offerings and prospering vaccine business buoy optimism for investors.
Align Technology (ALGN) Gains From Innovation, Macro Issues Ail
by Zacks Equity Research
In terms of innovation, Align Technology successfully launched its first subscription-based clear aligner program Doctor Subscription Program (DSP) worldwide.